Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologics Under Part D: Coinsurance, Cost Containment And Coverage Overlap

Executive Summary

Coinsurance appears to be the preferred cost-sharing method for biologics in Medicare Part D plans, according to an analysis of plan formularies by "The Pink Sheet."
Advertisement

Related Content

Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Specialty Pharmacies Adopting PBM Formulary Management Practices
Specialty Pharmacies Adopting PBM Formulary Management Practices
Medicare Rx Plans Likely To Focus On Managing Use Of Low-Cost Drugs
Part B/Part D Drug Coverage Shifts Should Await 2008, CMS Tells Congress

Topics

Advertisement
UsernamePublicRestriction

Register

PS046510

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel